Givosiran approved for use in the EU for Acute Hepatic Porphyria (AHP)

Approval of givosiran, an RNAi therapeutic targeting aminolevulinic acid synthase 1 was on the basis of results of the ENVISION Phase 3 Study which found a 74% reduction in the annualized composite rate of porphyria attacks vs placebo.


Biospace Inc.